Healthy Living

Kite Pharmaceuticals Submits Application for New Lymphoma Therapy

Kite Pharmaceuticals Submits Application for New Lymphoma Therapy

Kite Pharmaceuticals Submits Application for New Lymphoma Therapy

Kite Pharmaceuticals has officially requested marketing authorization of its new Car-T cell therapy via an MAA (marketing authorization application) to the European Medicines Agency (EMA). Their axicabtagene ciloleucel therapy is the first chimeric antigen receptor (CAR) T-cell therapy to ever be submitted to the EMA.